Search This Blog

Thursday, September 22, 2022

Vir Biotechnology Starts Phase 2 Trial Evaluating VIR-2218 and VIR-3434 for Chronic Hep D

  Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis 

– Novel combination strategy designed to
reduce HDV viremia and block viral entry –

https://www.biospace.com/article/releases/vir-biotechnology-announces-first-patient-dosed-in-the-phase-2-solstice-trial-evaluating-vir-2218-and-vir-3434-for-the-treatment-of-chronic-hepatitis-d-virus-infection/


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.